BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and inflammatory diseases.

BioCryst currently has two late-stage development programs: peramivir, a viral neuraminidase inhibitor for the treatment of influenza, and BCX4208, a PNP inhibitor for the treatment of gout. In addition, BioCryst has two preclinical programs advancing towards IND filings: BCX5191, a nucleoside analog inhibitor of HCV RNA polymerase (NS5B) for hepatitis C, and BCX4161, an oral inhibitor of plasma kallikrein for hereditary angioedema.

To learn more about BioCryst Pharmaceuticals please read the company’s 2011 annual report.

Read our annual report

Read our Corporate Factsheet

UPCOMING EVENTS

BioCryst to present at JMP Securities Research Conference on May 15, 2012 at 11:30 a.m. PT

BioCryst to present at Bank of America Merrill Lynch Healthcare Conference on May 16, 2012 at 5:00 p.m. PT

Connect to webcasts & presentations